Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

Combating cardiac complications caused by cancer treatment

Amie Goins has completed eight 5K runs in 2018. An impressive feat for a 46-year-old mother with a full-time job and two teenage sons to care for – downright astounding for a woman who was diagnosed with stage 2 breast cancer two days before Christmas last year. She's conquered months of treatment and difficult side effects while continuing to lace up.

26 Jun 2018

FDA approves new marijuana-based drug to treat rare and severe forms of epilepsy

The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older.

25 Jun 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Researchers identify culprit that spurs damaging inflammation following heart attack

Scientists have zeroed in on a culprit that spurs damaging inflammation in the heart following a heart attack. The guilty party is a type of immune cell that tries to heal the injured heart but instead triggers inflammation that leads to even more damage.

8 Jun 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018

Radiotherapy drug used for treating rare neuroendocrine cancers can be safe, effective for patients

A radiotherapy drug that treats the rare neuroendocrine cancers pheochromocytoma and paraganglioma can be both effective and safe for patients, according to the findings of a multi-center trial led by researchers in the Abramson Cancer Center of the University of Pennsylvania.

30 May 2018

New drug-delivering nanoparticle could offer better way to treat brain tumors

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median life expectancy for patients diagnosed with the disease is less than 15 months.

25 May 2018

FDA approves novel enzyme therapy for adults with rare and serious genetic disease

The U.S. Food and Drug Administration today approved Palynziq (pegvaliase-pqpz) for adults with a rare and serious genetic disease known as phenylketonuria (PKU).

25 May 2018

Celgene to share new and updated data around novel hematological therapies

Celgene Corporation today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association annual meeting in Stockholm, Sweden, from June 14-17, 2018.

22 May 2018

FDA approves new drug to treat thrombocytopenia in adults with chronic liver disease

The U.S. Food and Drug Administration today approved Doptelet (avatrombopag) tablets to treat low blood platelet count (thrombocytopenia) in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. This is the first drug approved by the FDA for this use.

22 May 2018

Infant formulas containing fructose pose risk to babies with hereditary fructose intolerance

Babies with inherited intolerance of fructose face a risk of acute liver failure if they are fed certain widely available formulas containing fructose, pediatricians and geneticists are warning.

18 May 2018

FDA OKs first non-opioid drug for adults with opioid withdrawal symptoms

The United States Food and Drugs Administration (FDA), in a statement this week, approved a new drug Lucemyra (lofexidine hydrochloride) for the treatment and alleviation of opioid symptom withdrawal symptoms in adults in whom the drugs have been withdrawn abruptly.

17 May 2018

Smart technology helps improve outcomes for patients with head and neck cancer

A federally funded, randomized clinical trial of 357 people receiving radiation for head and neck cancer, using mobile and sensor technology to remotely monitor patient symptoms, resulted in less severe symptoms related to both the cancer and its treatment (both general and cancer-related).

17 May 2018

Pfizer announces Phase 3 study results of LYRICA Oral Solution CV for pediatric epilepsy patients

Pfizer Inc. announced today positive top-line results of a Phase 3 study examining the use of LYRICA® Oral Solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four years of age.

17 May 2018

FDA approves new treatment to mitigate opioid withdrawal symptoms in adults

The U.S. Food and Drug Administration today approved Lucemyra (lofexidine hydrochloride) for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults.

17 May 2018

Musician Huey Lewis's struggle shines spotlight on Ménière's disease

The recent news revealing musician Huey Lewis's struggles with Ménière's disease has shined a spotlight on the neurological disorder. The symptoms, which include unpredictable bouts of dizziness, hearing loss and ringing in the ears, may get progressively worse over time and can greatly interfere with work, driving and daily activities.

16 May 2018

First epoetin alfa biosimilar receives FDA approval to treat certain types of anemia

The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection.

16 May 2018

Nausea News and Research

Further Reading

Combating cardiac complications caused by cancer treatment

FDA approves new marijuana-based drug to treat rare and severe forms of epilepsy

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Researchers identify culprit that spurs damaging inflammation following heart attack

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Radiotherapy drug used for treating rare neuroendocrine cancers can be safe, effective for patients

New drug-delivering nanoparticle could offer better way to treat brain tumors

FDA approves novel enzyme therapy for adults with rare and serious genetic disease

Celgene to share new and updated data around novel hematological therapies

FDA approves new drug to treat thrombocytopenia in adults with chronic liver disease

Infant formulas containing fructose pose risk to babies with hereditary fructose intolerance

FDA OKs first non-opioid drug for adults with opioid withdrawal symptoms

Smart technology helps improve outcomes for patients with head and neck cancer

Pfizer announces Phase 3 study results of LYRICA Oral Solution CV for pediatric epilepsy patients

FDA approves new treatment to mitigate opioid withdrawal symptoms in adults

Musician Huey Lewis's struggle shines spotlight on Ménière's disease

First epoetin alfa biosimilar receives FDA approval to treat certain types of anemia

New findings on extreme nausea and vomiting in pregnancy

First, marijuana. Are magic mushrooms next?

New survey shows 80% of oncologists have discussed medical marijuana use with patients

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News